SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is trending as escalating geopolitical tensions in the Middle East, driven by reports of US-Israeli strikes on Iran and subsequent retaliations, fuel widespread community discussion about potential oil supply disruptions, particularly regarding the Strait of Hormuz. Community sentiment is sharply divided between those anticipating a significant price surge and others expecting a rapid "sell the news" reversal.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLE is trending amidst escalating US-Iran conflict, with strikes on Gulf infrastructure and threats to the Strait of Hormuz fueling widespread fears of global oil supply disruptions and significant crude price surges. The community is actively discussing a flight to energy assets, positioning the sector for strong momentum even as broader markets anticipate risk-off sentiment.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd (INDO) is trending as escalating Middle East geopolitical tensions, including concerns over oil supply chokepoints like the Strait of Hormuz, are fueling community anticipation of surging crude prices and a potential short squeeze for this low-float energy stock.

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.

MediWound Ltd

MediWound is trending as investors eagerly anticipate a potential BARDA contract for its burn treatment NexoBrid, which recently showed strong efficacy in blast injuries, alongside promising advancements for its EscharEx chronic wound therapy. This momentum, including institutional interest and buyout speculation, is driving conversation despite polarized views on the stock's ability to break through current trading ranges.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending amid enthusiasm for positive Phase 3 clinical trial results for its HER2-positive breast cancer drug and encouraging lung cancer therapy data, fueling community discussions about its oncology pipeline and strategic pivot, even as some debate recent analyst upgrades against news of a partner offloading its stake.

Vanguard Group, Inc. - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

VOO is trending amidst heightened market uncertainty driven by Federal Reserve policy, geopolitical developments, and ongoing debates about the sustainability of valuations in the tech sector. Despite some community calls for a significant correction, many investors continue to favor VOO for its broad market exposure and long-term stability.

River is building a chain-abstraction stablecoin system that enables cross-chain collateral, yield, and liquidity—all without bridging.   Powered by the omni-CDP stablecoin satUSD, users can earn, leverage, and scale across different ecosystems natively.   River features the first omni-CDP module that allows users to collateralize assets on Chain A and mint stablecoin satUSD on Chain B—without bridging the assets.

River

RIVER CRYPTO is generating buzz driven by strategic funding, high-profile crypto endorsements, and potential major exchange listings. The community actively debates its extreme volatility and innovative stablecoin abstraction system amidst both bullish predictions and "pump and dump" concerns.

Nucor Corp. engages in the manufacture of steel products, and ferrous and non-ferrous materials. It operates through the following segments: Steel Mills, Steel Products, and Raw Materials. The Steel Mills segment consists of producing sheet, plate, structural, and bar steel. The Steel Products segment includes steel joists and joist girders, deck, fabricated concrete reinforcing, cold finished, fasteners, metal building systems, grating, tubular, piling products businesses, and wire mesh. The Raw Materials segment consists of direct reduced iron, and ferrous and nonferrous metals. The company was founded by Ransom E. Olds in 1905 and is headquartered in Charlotte, NC.

Nucor Corp.

Nucor is a top trending stock as the market digests recent mixed earnings performance against the backdrop of newly imposed steel tariffs, which are sparking community debate about a potential surge in domestic demand, further validated by a notable institutional stake.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiak Sciences is trending as investors eagerly await crucial clinical data readouts for its late-stage retinal disease programs, including KSI-101 in February and Tarcocimab in March. This high-stakes period, coupled with significant institutional accumulation by Baker Bros. and a recent de-risking capital raise, fuels community speculation about potential blockbuster outcomes or significant downside.

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Soleno Therapeutics Inc

Soleno Therapeutics is gaining significant attention as competitor Aardvark Therapeutics halted its Phase 3 trial for Prader-Willi Syndrome, reinforcing SLNO's VYKAT XR as the sole approved treatment for the condition and fueling community optimism for its market leadership.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


niks786

Nirmal Sharma